Diagnostic Usefulness of Immunohistochemical Staining for EMA in Psoriasis and Atopic Dermatitis Showing Psoriasiform Hyperplasia Authors: Sun Mun Jeong, Hyun Jin Kim, Chang Hyun Son, Jong Bin Park, Kee Suck Suh, Min Soo Jang Published: 2026 ABSTRACT AbstractBackgroundAtopic dermatitis (AD) and psoriasis (PSO) can share clinical and histopathologic features, complicating differentiation. Epithelial membrane antigen (EMA), a marker of epithelial differentiation, is used primarily in neoplastic diseases but is rarely assessed in inflammatory dermatoses. EMA expression in AD remains poorly defined.ObjectiveTo evaluate whether EMA immunohistochemistry (IHC) helps distinguish PSO from AD with psoriasiform hyperplasia.MethodsWe retrospectively reviewed 15 AD and 15 PSO patients showing psoriasiform hyperplasia. Clinical, histopathologic features, and EMA IHC patterns were assessed to compare AD and PSO.ResultsClinically, lichenification was more frequent in AD (80.0%) than in PSO (20.0%). Histopathologically, dilated capillaries were more frequent in PSO (100.0%) than in AD (46.7%), whereas dermal eosinophils were present in AD (73.3%) but not in PSO (0%); both differences were statistically significant. Moderate-to-severe acanthosis, parakeratosis, suprapapillary plate thinning, pallor of the upper epidermis, Munro’s microabscesses, and diminished granular layer tended to be more frequently observed in PSO, without statistical significance. Regarding EMA, strong expression was more common in AD (73.3%) than in PSO (6.7%), with overlap in moderate staining intensity. The mean intensity grade was significantly higher in AD than in PSO (3.93 vs. 1.93). Diffuse epidermal expression was also more frequent in AD (86.7% vs. 16.7%) among EMA-positive cases.ConclusionEMA IHC may provide adjunctive evidence when distinguishing PSO from AD with psoriasiform hyperplasia. Strong and diffuse epidermal EMA expression may favor AD. Because intensity patterns can overlap, EMA should be interpreted in conjunction with clinical and histopathologic features.Keywords: Atopic dermatitis, Epithelial membrane antigen, Histocytochemistry, Psoriasis INTRODUCTION Atopic dermatitis (AD) and psoriasis (PSO) are common inflammatory skin diseases with different underlying mechanisms, thus exhibiting different clinical features and requiring distinct treatments1,2. AD often manifests as erythematous patches and plaques with excoriated papules, crusts, and lichenification, frequently affecting flexural areas3. PSO is characterized by well-demarcated, bright-red plaques with thick, silvery-white scales, typically on extensor surfaces. Although these diseases generally present distinct clinical manifestations, they can share clinical and histopathologic features4, and it can often be challenging to distinguish between them. They frequently show overlapping clinical features characterized by thickened skin with scales, corresponding to epidermal hyperplasia with parakeratosis on histopathology, particularly among Asian populations5. Thus, adjunctive diagnostic tools beyond conventional hematoxylin and eosin (H&E) evaluation are needed. Epithelial membrane antigen (EMA), an epithelial differentiation marker, is a transmembrane glycoprotein that plays a role in a wide range of cellular functions, including regulation of cell proliferation, growth, differentiation, migration, and invasion6,7. These findings have been extensively studied in numerous studies focusing on neoplastic conditions, including Paget’s disease, squamous cell carcinoma, and adnexal neoplasms8. However, EMA expression in inflammatory skin diseases has been less well characterized8,9,10. Abdou et al.9 reported epidermal EMA expression in psoriatic lesions and noted that staining intensity positively correlated with the degree of epidermal acanthosis. Drawing on these earlier findings, we examined whether there were differences in EMA staining patterns in Asian AD and PSO, both of which presented with psoriasiform hyperplasia. MATERIALS AND METHODS Subjects This study was conducted on 15 patients with AD and 15 patients with PSO, all of whom presented with scaly thickened lesions corresponding histologically to psoriasiform epidermal hyperplasia with parakeratosis, between December 2014 and June 2022 in the Department of Dermatology, Kosin University Gospel Hospital, Busan, Korea. All patients were diagnosed through a comprehensive evaluation of clinical and histopathologic features. We excluded patients with: (i) use of topical corticosteroids or calcineurin inhibitors within 2 weeks before biopsy; and (ii) biopsies from special sites (palms/soles) because site-specific histology could bias EMA interpretation. This study was approved by the Institutional Review Board of Kosin University Gospel Hospital (approval #2023-03-029). Clinical assessment Medical records and clinical photographs of 30 patients were reviewed. Age, sex, disease duration, symptoms, clinical features, and disease severity were assessed for each patient. To evaluate the severity of the disease, the mean eczema area and severity index (EASI) score was calculated for AD, and the mean psoriasis area and severity index (PASI) score was calculated for PSO. Histopathologic evaluation Skin samples were obtained, embedded in paraffin, and prepared as slides that were stained with H&E. The slides were examined independently by two blinded dermatopathologists for the following histologic parameters: degree of acanthosis, spongiosis, dilated capillaries in the papillary dermis, parakeratosis, suprapapillary plate thinning, pallor of the upper epidermis, Munro’s microabscesses (neutrophil accumulation in the stratum corneum), diminished granular layer, and eosinophils in the dermis. Immunohistochemical evaluation Immunostaining was performed on an automated Leica BOND-MAX system (Leica Biosystems, Newcastle, UK). Slides were incubated with a ready-to-use anti-EMA antibody (EMA, clone E29; BOND RTU, Leica Biosystems) for 15–30 minutes at ambient temperature. Detection employed the BOND Polymer Refine Detection kit with DAB chromogen (Leica Biosystems), followed by hematoxylin counterstaining and bluing. For quantitative evaluation of EMA immunoreactivity, an image analysis program (ImageJ, NIH, Bethesda, MD, USA) was used. Positive pixels were selected and the positive staining area (PSA) of EMA in the epidermis per total epidermal area (TEA) was calculated under constant magnification. For each frame, the tracing was repeated three times, and the mean was determined. To minimize subjectivity, intensity grades were derived from the PSA/TEA ratio quantified using ImageJ for each specimen. A 6-point semi-quantitative scale was used to grade the intensity: 0 (PSA/TEA: 0%), 1 (PSA/TEA≤20%), 2 (20%80%). The mean grade of the intensity was calculated. The grade of intensity was classified into four levels: absent (0), mild (1), moderate (2, 3), and strong (4, 5). The distribution of expression was divided into diffuse (staining across the entire epidermis) or focal (staining limited to part of the epidermis). All slides were evaluated by two independent dermatopathologists. Discrepancies were resolved through discussion between the two reviewers. Statistical analysis Statistical analysis was performed using IBM SPSS Statistics ver. 30.0 (IBM Corp., Armonk, NY, USA). Categorical variables are presented as counts and percentages and were compared between groups using two-tailed Fisher’s exact tests. Continuous variables were assessed with the two-tailed Mann-Whitney U test. All tests were two-sided, and p<0.05 was considered statistically significant. RESULTS Clinical assessment The AD group comprised ten men (66.7%) and five women (33.3%); the PSO group included 12 men (80.0%) and three women (20.0%). For each of AD and PSO, the mean age of patients at the time of diagnosis was 42.2±17.1 and 50.9±17.3 years and the mean disease duration was 107.6±121.2 and 138.8±101.9 months. There were no significant differences in sex ratio, age, or disease duration. Pruritus was reported by all AD patients and by 80% of PSO patients. Patches and plaques were common in both diseases. Scales were seen in most patients (80.0% in AD and 100.0% in PSO). Lichenification was more frequent in AD (80.0%) than in PSO (20.0%). Crusts were also more common in AD than in PSO (86.7% vs. 53.3%), although only lichenification reached statistical significance. The mean EASI score was 15.7 (range, 7.4–33.2) in the AD group and the mean PASI score was 8.5 (range, 3.0–21.9) in the PSO group (Table 1, Fig. 1). Table 1Demographics and clinical findings of AD and PSOVariablesAD (n=15)PSO (n=15)p-valueAge (yr)42.2 (16–67)50.9 (24–79)0.267Sex0.682Male10 (66.7)12 (80.0)Female5 (33.3)3 (20.0)Duration (mo)107.6 (2–360)138.8 (6–360)0.074Symptoms0.224Pruritus15 (100.0)12 (80.0)None0 (0.0)3 (20.0)Clinical featuresPatch15 (100.0)15 (100.0)NAPlaque10 (66.7)13 (86.7)0.390Scale12 (80.0)15 (100.0)0.224Lichenification12 (80.0)3 (20.0)0.003* Crust13 (86.7)8 (53.3)0.109Disease severityEASI score15.7 (7.4–33.2)NAPASI scoreNA8.5 (3.0–21.9)Values are presented as number (%) or mean (range).AD: atopic dermatitis, PSO: psoriasis, NA: not applicable, EASI: eczema area and severity index, PASI: psoriasis area and severity index.*Statistically significant (p<0.05). Demographics and clinical findings of AD and PSO Values are presented as number (%) or mean (range). AD: atopic dermatitis, PSO: psoriasis, NA: not applicable, EASI: eczema area and severity index, PASI: psoriasis area and severity index. *Statistically significant (p<0.05). Clinical and histopathologic findings of atopic dermatitis and psoriasis. (A) Erythematous scaly excoriated and serum-crusted patches and plaques on the back in atopic dermatitis. (B) Flesh-colored to erythematous scaly patches and plaques on the back in psoriasis. (C, D) Histopathologic findings of atopic dermatitis and psoriasis show similar psoriasiform features, including severe acanthosis, parakeratosis, dilated capillaries, diminished granular layer, and inflammatory cell infiltration in the dermis (hematoxylin and eosin, ×100). Histopathologic findings Epidermal hyperplasia was observed in all patients. Dilated papillary dermal capillaries were more frequent in PSO (100.0%) than in AD (46.7%) (p=0.002), and dermal eosinophils were present in AD (73.3%) but not in PSO (0%) (p<0.001). Moderate-to-severe acanthosis, parakeratosis, thinning of the suprapapillary plate, pallor of the upper epidermis, Munro’s microabscesses, and diminished granular layer were more often observed in PSO, though differences were not statistically significant. Spongiosis was more prevalent in AD (40.0%) than in PSO (13.3%), without statistical significance (Table 2, Fig. 1). Table 2Histopathologic findings of AD and PSOVariablesAD (n=15)PSO (n=15)p-valueAcanthosis (degree)15 (100.0)15 (100.0)0.245Mild7 (46.7)3 (20.0)Moderate to severe8 (53.3)12 (80.0)Spongiosis6 (40.0)2 (13.3)0.215Dilated capillaries in papillary dermis7 (46.7)15 (100.0)0.002* Parakeratosis11 (73.3)14 (93.3)0.330Suprapapillary thinning4 (26.7)10 (66.7)0.066Pallor of the upper epidermis2 (13.3)8 (53.3)0.070Munro’s microabscesses3 (20.0)8 (53.3)0.128Diminished granular layer8 (53.3)13 (86.7)0.109Eosinophils in dermis11 (73.3)0 (0.0)<0.001* Values are presented as number (%).AD: atopic dermatitis, PSO: psoriasis.*Statistically significant (p<0.05). Histopathologic findings of AD and PSO Values are presented as number (%). AD: atopic dermatitis, PSO: psoriasis. *Statistically significant (p<0.05). Immunohistochemical findings All AD specimens showed epidermal EMA positivity, compared with 80.0% of PSO specimens. In terms of staining intensity, the mean grade was higher in AD than in PSO (3.93 vs. 1.93, p<0.001). Strong expression of EMA in the epidermis was more frequent in AD than in PSO (73.3% vs. 6.7%, p<0.001). In terms of staining distribution, diffuse epidermal staining was also more common in AD than in PSO (86.7% vs. 16.7%, p<0.001) among EMA-positive cases. Both groups exhibited membranous staining patterns. EMA expression was not observed in the dermis in any group, except in the sweat duct and sebaceous gland (Table 3, Fig. 2). Table 3Immunohistochemical findings of EMA stain in AD and PSOVariablesAD (n=15)PSO (n=15)p-valueExpression positivity0.224Positive15 (100.0)12 (80.0)Negative0 (0.0)3 (20.0)Staining intensity<0.001* None0 (0.0)3 (20.0)Mild1 (6.7)5 (33.3)Moderate3 (20.0)6 (40.0)Strong11 (73.3)1 (6.7)Mean grade of intensity3.93±0.931.93±1.16<0.001* Staining distribution† <0.001* Focal2 (13.3)10 (83.3)Diffuse13 (86.7)2 (16.7)Values are presented as number (%) or mean ± standard deviation.EMA: epithelial membrane antigen, AD: atopic dermatitis, PSO: psoriasis.*Statistically significant (p<0.05).†Distribution was calculated among EMA-positive cases. Immunohistochemical findings of EMA stain in AD and PSO Values are presented as number (%) or mean ± standard deviation. EMA: epithelial membrane antigen, AD: atopic dermatitis, PSO: psoriasis. *Statistically significant (p<0.05). †Distribution was calculated among EMA-positive cases. Immunohistochemical findings of EMA staining in atopic dermatitis and psoriasis. (A) Strong and diffuse expression (grade 5) of EMA in the epidermis is shown in atopic dermatitis. (B) Mild and focal expression (grade 1) of EMA in the epidermis is shown in psoriasis (EMA, ×200). EMA: epithelial membrane antigen. DISCUSSION Distinguishing AD from PSO becomes particularly challenging when both present with psoriasiform hyperplasia on histopathology, a scenario not uncommon in Asian populations5,11,12. PSO is recognized predominantly as an interleukin (IL)-23/Th17-related immune disease5, accompanied by IL-2213,14. AD is associated with multiple polar immune pathways, marked by the predominance of Th2 activation accompanied by activated Th17 and Th22 T-cells5,12,13,15. Despite the distinctive features of these diseases, there are many overlaps in their clinical features, underlying immune system, and the resulting tissue structure and function. Recent investigations have revealed distinct immunologic characteristics in Asian AD compared to those of European American AD. Asian AD has prominent Th17- and Th22-related cytokines and thereby exhibits a more psoriasiform phenotype. In our cohort selected for psoriasiform hyperplasia, several conventional clinicopathologic clues remained informative16,17. Clinically, lichenification was significantly more frequent in AD than in PSO (80.0% vs. 20.0%). Histopathologically, dermal eosinophils were observed only in AD (73.3% vs. 0%), whereas dilated papillary dermal capillaries were more frequent in PSO (100.0% vs. 46.7%). These findings underscore that, even in psoriasiform presentations, integrated assessment of clinical morphology and key histopathologic features provides the primary diagnostic framework. Against this clinicopathologic background, we evaluated whether epidermal EMA staining could provide additional adjunctive information. Abdou et al.9 reported epidermal EMA expression in chronic plaque PSO and linked its intensity to the degree of acanthosis, implying that keratinocytic hyperplasia can up-regulate EMA. However, to our knowledge, EMA expression in AD had not been examined. Our study addresses this gap by comparing EMA immunoreactivity between AD and PSO. The added value of our work lies in how EMA behaves across the two diseases under psoriasiform selection: AD shows stronger and more diffuse epidermal EMA staining, whereas PSO tends toward weaker, focal staining. This finding suggests that EMA expression is influenced not only by epidermal acanthosis but also by additional factors that differ between AD and PSO. Notably, a degree of overlap was observed in moderate staining intensity. As shown in Table 3, moderate EMA intensity was present in 40% of PSO cases. Given that intensity grading can be challenging to operationalize in routine settings, the epidermal distribution pattern (diffuse vs. focal) may be more readily applicable than subtle distinctions in staining intensity and should be interpreted in conjunction with the overall clinicopathologic context. Mechanistically, this pattern is biologically plausible. Asian AD is characterized by prominent Th17 and Th22 signals, with elevated IL-22 in both lesional and even non-lesional skin5,12,18,19,20. IL-22 drives epidermal hyperplasia, hypogranulosis, and parakeratosis—the very changes that confer a psoriasiform look19. Furthermore, Nograles et al.20 have reported that AD lesions showed higher expression of IL-22 compared to that in PSO lesions. Given that previous studies have suggested that IL-22 can induce EMA expression through STAT3 production21,22,23, we hypothesize that the increased expression of EMA in AD lesions compared to that in PSO lesions in our study may be attributed to the upregulation of IL-22/STAT3 in AD. While our study was not designed to prove causality, this cytokine-to-EMA linkage can provide a coherent framework for future mechanistic validation. This study is limited by its retrospective, single-center design, selection restricted to psoriasiform cases, and modest sample size that may affect precision of estimates. We did not measure tissue cytokines alongside EMA, so direct molecular correlation could not be assessed. Future multicenter studies integrating immunohistochemistry (IHC) with cytokines should test the proposed IL-22–EMA axis and establish cutoffs for routine practice. In conclusion, epidermal EMA IHC may provide supportive evidence when distinguishing PSO from AD with psoriasiform hyperplasia; however, given overlap in moderate staining intensity, EMA should be interpreted as an adjunct to established clinical and histopathologic features rather than a stand-alone discriminator.